Evidence map›Paper›PMID 40956363›Full record

ArticleEsophagus : official journal of the Japan Esophageal Society2026

Additional treatment for esophageal cancer patients with incomplete resection due to the surrounding organ invasion: a nationwide survey of 45 Japanese centers.

Akihiko Okamura, Masayuki Watanabe, Jun Okui, Satoru Matsuda, Yoichi Hamai, Naoki Takahashi, Shinsuke Sato, Tetsuya Abe, Hirotaka Ishida, Hironobu Goto and 21 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Esophagus : official journal of the Japan Esophageal Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors.

Akihiko Okamura *Department of Esophageal Surgery, Cancer Institute Hospital of Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo, 135-8550, Japan.
Masayuki WatanabeDepartment of Esophageal Surgery, Cancer Institute Hospital of Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo, 135-8550, Japan. masayuki.watanabe@jfcr.or.jp.ORCID 0000-0003-0298-1597
Jun Okui *Department of Preventive Medicine and Public Health, School of Medicine, Keio University, Tokyo, Japan.
Satoru Matsuda *Department of Surgery, School of Medicine, Keio University, Tokyo, Japan.
Yoichi HamaiDepartment of Surgical Oncology, Hiroshima University, Hiroshima, Japan.
Naoki TakahashiDepartment of Esophageal Surgery, Cancer Institute Hospital of Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo, 135-8550, Japan.
Shinsuke SatoDepartment of Gastroenterological Surgery, Shizuoka General Hospital, Shizuoka, Japan.
Tetsuya AbeDepartment of Gastroenterological Surgery, Aichi Cancer Center Hospital, Aichi, Japan.
Hirotaka IshidaDepartment of Surgery, Tohoku University Graduate School of Medicine, Miyagi, Japan.
Hironobu GotoDivision of Gastrointestinal Surgery, Department of Surgery, Graduate School of Medicine, Kobe University, Hyogo, Japan.
Takeo BambaDepartment of Gastroenterological Surgery, Niigata Cancer Center, Niigata, Japan.
Tomokazu KakishitaDepartment of Gastroenterological Surgery, National Hospital Organization Shikoku Cancer Center, Ehime, Japan.
Eisuke BookaDepartment of Surgery, Hamamatsu University School of Medicine, Shizuoka, Japan.
Hidehiko KitagamiDepartment of Gastroenterological Surgery, Keiyukai Sapporo Hospital, Hokkaido, Japan.
Shirou KuwabaraDepartment of Digestive and General Surgery, Niigata City General Hospital, Niigata, Japan.
Yasue KimuraDepartment of Gastroenterological Surgery, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
Keisuke KosumiDepartment of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
Sohei MatsumotoDepartment of Surgery, Nara Medical University, Nara, Japan.
Masanobu NakajimaDepartment of Upper Gastrointestinal Surgery, Dokkyo Medical University, Tochigi, Japan.
Seiya InoueDepartment of Thoracic, Endocrine Surgery and Oncology, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan.
Hiroyuki KitagawaDepartment of Surgery, Kochi Medical School, Kochi, Japan.
Susumu ShibasakiDepartment of Surgery, Fujita Health University, Aichi, Japan.
Noriaki SadanagaDepartment of Surgery, Saiseikai Fukuoka General Hospital, Fukuoka, Japan.
Katsushi TakebayashiDepartment of Surgery, Shiga University of Medical Science, Shiga, Japan.
Toshiaki ShichinoheDepartment of Gastroenterological Surgery II, Faculty of Medicine, Hokkaido University, Hokkaido, Japan.
Hirofumi KawakuboDepartment of Surgery, School of Medicine, Keio University, Tokyo, Japan.
Yoshihiro KakejiDivision of Gastrointestinal Surgery, Department of Surgery, Graduate School of Medicine, Kobe University, Hyogo, Japan.
Koji KonoDepartment of Gastrointestinal Tract Surgery, Fukushima Medical University School of Medicine, Fukushima, Japan.
Yuko KitagawaDepartment of Surgery, School of Medicine, Keio University, Tokyo, Japan.
Hiroya TakeuchiDepartment of Surgery, Hamamatsu University School of Medicine, Shizuoka, Japan.
Japan Esophageal Society Research Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWe occasionally experience incomplete resection of esophageal cancer due to the surrounding organ invasion. The efficacy of additional treatment in these cases is unknown.

methodsWe studied 445 patients with esophageal squamous cell carcinoma who were unable to undergo curative esophagectomy due to cancer invasion to the surrounding organs at 45 esophageal centers in Japan. Survival outcomes were compared based on the additional treatment modalities.

resultsPostoperatively, 175 (40.0%) received no additional treatment, while 59 (13.5%), 153 (35.0%), and 50 (11.4%) received additional chemotherapy, chemoradiotherapy, or radiotherapy, respectively. The three-year disease progression and overall survival rates were 90.6% (95% confidence interval 87.2-93.1%) and 15.4% (95% confidence interval 12.2-19.3%), respectively. Multivariable analysis revealed that chemotherapy, chemoradiotherapy, and radiotherapy were all independently associated with reduced disease progression (hazard ratios [95% confidence intervals]: 0.57 [0.40-0.81], 0.52 [0.39-0.69], and 0.48 [0.33-0.72], respectively). Meanwhile, additional treatment with chemotherapeutic agents (chemotherapy and chemoradiotherapy) was independently associated with better overall survival (hazard ratios [95% confidence intervals]: 0.51 [0.35-0.73] and 0.59 [0.44-0.79], respectively); however, radiotherapy alone had a limited impact (hazard ratio [95% confidence interval]: 0.74 [0.50-1.10]).

conclusionsAny additional treatment could suppress disease progression after incomplete resection, but radiotherapy alone has a limited effect. Additional systemic chemotherapeutics may increase patient survival.

Indexed as

Carcinoma, Squamous CellEsophageal NeoplasmsEsophagectomyAgedAged, 80 and overChemoradiotherapyCombined Modality TherapyDisease ProgressionEast Asian PeopleEsophageal Squamous Cell CarcinomaFemaleHumansJapanMaleMiddle AgedNeoplasm InvasivenessAdditional therapyEsophagectomyIncomplete resectionOrgan invasionSquamous cell carcinoma

Identifiers

PMID40956363

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.